Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. to recover losses incurred by shareholders due to alleged securities fraud between February 21, 2025, and August 28, 2025 [2]. Group 1: Lawsuit Details - The lawsuit alleges that the defendants made false statements and concealed information regarding Telix's progress on prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects, which were materially false and misleading [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to visit the provided link to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Law Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].
Class Action Lawsuit Filed: Telix Pharmaceuticals Ltd. (TLX) - Join by January 9, 2026 - Contact Levi & Korsinsky